Literature DB >> 24193096

Silica-F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T1 magnetic resonance relaxivity.

Benedict You Wei Hsu1, Miao Wang, Yu Zhang, Vimalan Vijayaragavan, Siew Yee Wong, Alex Yuang-Chi Chang, Kishore Kumar Bhakoo, Xu Li, John Wang.   

Abstract

To properly engineer MnO nanoparticles (MONPs) of high r1 relaxivity, a nanohybrid coating consisting of silica and F127 (PEO106PPO70PEO106) is designed to encapsulate MONPs. Achieved by an interfacial templating scheme, the nanohybrid encapsulating layer is highly permeable and hydrophilic to allow for an optimal access of water molecules to the encapsulated manganese oxide core. Hence, the efficacy of MONPs as MRI contrast agents is significantly improved, as demonstrated by an enhancement of the MR signal measured with a pre-clinical 7.0 T MRI scanner. The nanohybrid encapsulation strategy also confers high colloidal stability to the hydrophobic MONPs by the surface decoration of PEO chains and a small overall diameter (<100 nm) of the PEO-SiO2 nanohybrid-encapsulated MONPs (PEOMSNs). The PEOMSNs are not susceptible to Mn-ion leaching, and their biocompatibility is affirmed by a low toxicity profile. Moreover, these hybrid nanocapsules exhibit a nano-rattle structure, which would favor the facile loading of various therapeutic reagents for theranostic applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24193096     DOI: 10.1039/c3nr04378a

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  2 in total

Review 1.  Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.

Authors:  Xiaoxia Cai; Qingxia Zhu; Yun Zeng; Qi Zeng; Xueli Chen; Yonghua Zhan
Journal:  Int J Nanomedicine       Date:  2019-10-21

2.  Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications.

Authors:  Benedict You Wei Hsu; Georgia Kirby; Aaron Tan; Alexander M Seifalian; Xu Li; John Wang
Journal:  RSC Adv       Date:  2016-05-10       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.